F500 Pharma & Biotech · Pharmaceuticals · No confirmed finding (unverified, not clean)
Regeneron Pharmaceuticals
Headline
Nothing confirmed
Nothing company-specific confirmed this pass.
Not independently verified. Verification status: Unverified - heuristic first draft. Publish state: draft unverified.
What this pass recorded. Nothing company-specific confirmed this pass. Same analysis as the other manufacturers on this tab - limited direct consumer relationship, real indirect patient data through trials and support programmes, and shared-distributor exposure. Recommend the Cencora notification list as the efficient follow-up for every unconfirmed row in this tab rather than company-by-company searching.
- Severity
- Evidence tierUnassigned
- Claims confirmed
- Last verified2026-08-04
Primary source. None recorded — Unverified - heuristic first draft.
Terms
Arbitration
Not independently confirmed this pass — standard binding arbitration + class action waiver expected.
Data sharing
Not independently confirmed this pass with a company-specific consumer data lawsuit beyond the shared industry findings below. SHARED FINDING ACROSS MANY PHARMA COMPANIES: (1) A 2024 breach at CENCORA (a major pharmaceutical distributor, documented separately in the Healthcare Providers tab of this tracker) exposed patient information — names, addresses, birthdates, health diagnoses, and prescriptions — for patients receiving medications marketed by this company, among more than a dozen other manufacturers (Bayer, Genentech, AbbVie, Novartis, Regeneron, GSK, and others) whose distribution flowed through Cencora. (2) A SEPARATE, PENDING 2026 lawsuit (filed Feb. 12, 2026 in the U.S. District Court for the Northern District of Illinois, with three companion cases, under the state's Genetic Information Privacy Act, per Tempus's Q2 2026 10-Q) alleges that Tempus AI collected and disclosed genetic information of Ambry Genetics customers without prior written consent, used it to train AI models and shares it with pharmaceutical companies; the reporting reviewed does not name the pharmaceutical recipients, so this row does not assert that Regeneron received such data (allegations only). A reported Tempus CFO 'record year' remark was not verified.
Fees and billing
Not itemized this pass.
Contacts
Privacy contact. Not recorded.
Legal notice. Not verified this pass. If publicly traded: SEC Form 10-K cover page gives the official corporate address; the Secretary of State business-entity search in the state of incorporation gives the registered agent, which must accept service. If private: the state registered agent is usually the only reliable route.
Mailing address. Not recorded.
Evidence
No claims have been itemized for this row yet.
No sources are on file for this row yet.
Source vault
Link status: Candidate - not yet fetched
| Document | Last fetch | |
|---|---|---|
| Privacy policy See Regeneron Pharmaceuticals's own published privacy policy | Not fetched yet | NOT CONFIRMED |
| Terms of service See Regeneron Pharmaceuticals's own published terms of service | Not fetched yet | NOT CONFIRMED |
| Website No URL recorded | Not fetched yet | — |
| Primary source No URL recorded Verification: Unverified - heuristic first draft | Not fetched yet | — |
Enforcement
No enforcement actions are linked to this row.
State statute
No HQ state on file, so no state statute applies by headquarters.